Sezer Acar
Sezer Acar has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Behzat Özkan
Department of Pediatric Endocrinology, University of Health Sciences, İzmir Faculty of Medicine, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Turkey
12 shared publications - Korcan Demir
Dokuz Eylul University Faculty of Medicine
9 shared publications - Ayhan Abacı
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey
8 shared publications - Özlem Nalbantoğlu
Department of Pediatric Endocrinology, University of Health Sciences, İzmir Faculty of Medicine, Dr. Behçet Uz Children’s Hospital, İzmir, Türkiye
8 shared publications - Özge Köprülü
Department of Pediatric Endocrinology University of Health Sciences, Dr. Behçet Uz Children's Hospital İzmir Turkey
7 shared publications - Ece Böber
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey
6 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 31 (5) , 265-281
An update on the genetic causes and treatment of hypophosphatemic rickets
Hypophosphatemic rickets (HR) results from impaired renal phosphate reabsorption caused either by genetic defects in renal phosphate cotransporters or by increased levels of phosphaturic mediators (phosphatonins). Fibroblast growth factor 23 (FGF23) is the principal regulator of phosphate metabolism and interacts with several hormonal and molecular pathways to maintain phosphate homeostasis. Variants in genes such as PHEX, FGF23, DMP1, ENPP1, FAM20C, and others lead to inherited forms of HR, and HR may also occur as part of several syndromic conditions. Affected patients typically present with short stature, skeletal deformities, bone pain, muscle weakness, dental abnormalities, and characteristic radiographic abnormalities. Laboratory findings usually include hypophosphatemia, normal or mildly elevated parathyroid hormone levels, and markedly increased alkaline phosphatase. Conventional therapy with oral phosphate and active vitamin D improves many metabolic abnormalities but rarely leads to full correction. The development of burosumab, a monoclonal antibody targeting FGF23, has transformed treatment by improving biochemical parameters, rickets severity, growth, and quality of life. This review summarizes current knowledge regarding the molecular mechanisms, clinical manifestations, diagnostic work-up, classification, and treatment strategies for HR, with particular emphasis on advances in targeted therapy.
- 31 October 2026
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 31 (5) , 265-281
Open AccessAn update on the genetic causes and treatment of hypophosphatemic rickets
Hypophosphatemic rickets (HR) results from impaired renal phosphate reabsorption caused either by genetic defects in renal phosphate cotransporters or by increased levels of phosphaturic mediators (phosphatonins). Fibroblast growth factor 23 (FGF23) is the principal regulator of phosphate metabolism and interacts with several hormonal and molecular pathways to maintain phosphate homeostasis. Variants in genes such as PHEX, FGF23, DMP1, ENPP1, FAM20C, and others lead to inherited forms of HR, and HR may also occur as part of several syndromic conditions. Affected patients typically present with short stature, skeletal deformities, bone pain, muscle weakness, dental abnormalities, and characteristic radiographic abnormalities. Laboratory findings usually include hypophosphatemia, normal or mildly elevated parathyroid hormone levels, and markedly increased alkaline phosphatase. Conventional therapy with oral phosphate and active vitamin D improves many metabolic abnormalities but rarely leads to full correction. The development of burosumab, a monoclonal antibody targeting FGF23, has transformed treatment by improving biochemical parameters, rickets severity, growth, and quality of life. This review summarizes current knowledge regarding the molecular mechanisms, clinical manifestations, diagnostic work-up, classification, and treatment strategies for HR, with particular emphasis on advances in targeted therapy.
- 12 May 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (6) , 573-581
Genetic evaluation of a group of patients with transient congenital hypothyroidism by targeted exome sequencing
Objectives: Transient congenital hypothyroidism (TCH) is characterized by congenital hypothyroidism (CH) which spontaneously resolves in the first years of life. While most cases are sporadic, several studies from worldwide showed variants in DUOX2 , DUOXA2, TSHR genes in the etiology of TCH. The aim of our study is to evaluate the genetic etiology of TCH. Methods: A total of 54 patients from 50 families with TCH were included the study. The age at diagnosis, age at time of drug discontinuation, gender, consanguinity, the presence of additional examination findings, venous fT4 and TSH levels at the time of diagnosis, at time of drug discontinuation and at the last visit, the follow-up data and genetic characteristics were obtained from records. Results: A total of 54 patients from 50 families [59.3 % male (n=32) and 40.7 % female (n=22)] with TCH were included in the study. Pathogenic variants were detected in 15 out of 54 patients. 10 different DUOX2 variants (c.1060C>T, c.1547G>A, c.2597T>G, c.3314T>C, c.3382C>A, c.3509A>C, c.3790A>G, c.4445C>T, c.28del, c.533G>T) were identified in 11 patients (2 homozygous, 3 compound heterozygous, and 6 heterozygous). Conclusions: Our findings suggest that DUOX2 variants are the main genetic cause of TCH. We reported novel variants in the DUOX2 and TSHR genes that expand their mutational spectrum. These findings support the need for incorporating molecular analysis into the diagnostic evaluation of TCH, not only to improve our knowledge of its genetic underly, but also to provide valuable insights for long-term follow-up, family counseling, and personalized management strategies.
- 12 May 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (6) , 573-581
Genetic evaluation of a group of patients with transient congenital hypothyroidism by targeted exome sequencing
Objectives: Transient congenital hypothyroidism (TCH) is characterized by congenital hypothyroidism (CH) which spontaneously resolves in the first years of life. While most cases are sporadic, several studies from worldwide showed variants in DUOX2 , DUOXA2, TSHR genes in the etiology of TCH. The aim of our study is to evaluate the genetic etiology of TCH. Methods: A total of 54 patients from 50 families with TCH were included the study. The age at diagnosis, age at time of drug discontinuation, gender, consanguinity, the presence of additional examination findings, venous fT4 and TSH levels at the time of diagnosis, at time of drug discontinuation and at the last visit, the follow-up data and genetic characteristics were obtained from records. Results: A total of 54 patients from 50 families [59.3 % male (n=32) and 40.7 % female (n=22)] with TCH were included in the study. Pathogenic variants were detected in 15 out of 54 patients. 10 different DUOX2 variants (c.1060C>T, c.1547G>A, c.2597T>G, c.3314T>C, c.3382C>A, c.3509A>C, c.3790A>G, c.4445C>T, c.28del, c.533G>T) were identified in 11 patients (2 homozygous, 3 compound heterozygous, and 6 heterozygous). Conclusions: Our findings suggest that DUOX2 variants are the main genetic cause of TCH. We reported novel variants in the DUOX2 and TSHR genes that expand their mutational spectrum. These findings support the need for incorporating molecular analysis into the diagnostic evaluation of TCH, not only to improve our knowledge of its genetic underly, but also to provide valuable insights for long-term follow-up, family counseling, and personalized management strategies.
- Open Access
- 9 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (22)
Recessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndrome
Understanding the genetic causes of diseases that affect pancreatic β cells and neurons can give insights into pathways essential for both cell types. Microcephaly, epilepsy, and diabetes syndrome (MEDS) is a congenital disorder with two known etiological genes, IER3IP1 and YIPF5 . Both genes encode proteins involved in endoplasmic reticulum (ER) to Golgi trafficking. We used genome sequencing to identify 6 individuals with MEDS caused by biallelic variants in the potentially novel disease gene TMEM167A . All had neonatal diabetes (diagnosed at TMEM167A is highly expressed in developing and adult human pancreas and brain. To gain insights into the mechanisms leading to diabetes, we silenced TMEM167A in EndoC-βH1 cells and knocked-in one patient’s variant, p.Val59Glu, in induced pluripotent stem cells (iPSCs). Both TMEM167A depletion in EndoC-βH1 cells and the p.Val59Glu variant in iPSC-derived β cells sensitized β cells to ER stress. The p.Val59Glu variant impaired proinsulin trafficking to the Golgi and induced iPSC-β cell dysfunction. The discovery of TMEM167A variants as a genetic cause of MEDS highlights a critical role of TMEM167A in the ER to Golgi pathway in β cells and neurons.
- 9 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (22)
Open AccessRecessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndrome
Understanding the genetic causes of diseases that affect pancreatic β cells and neurons can give insights into pathways essential for both cell types. Microcephaly, epilepsy, and diabetes syndrome (MEDS) is a congenital disorder with two known etiological genes, IER3IP1 and YIPF5 . Both genes encode proteins involved in endoplasmic reticulum (ER) to Golgi trafficking. We used genome sequencing to identify 6 individuals with MEDS caused by biallelic variants in the potentially novel disease gene TMEM167A . All had neonatal diabetes (diagnosed at TMEM167A is highly expressed in developing and adult human pancreas and brain. To gain insights into the mechanisms leading to diabetes, we silenced TMEM167A in EndoC-βH1 cells and knocked-in one patient’s variant, p.Val59Glu, in induced pluripotent stem cells (iPSCs). Both TMEM167A depletion in EndoC-βH1 cells and the p.Val59Glu variant in iPSC-derived β cells sensitized β cells to ER stress. The p.Val59Glu variant impaired proinsulin trafficking to the Golgi and induced iPSC-β cell dysfunction. The discovery of TMEM167A variants as a genetic cause of MEDS highlights a critical role of TMEM167A in the ER to Golgi pathway in β cells and neurons.
- Open Access
- 1 August 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , e362-e367
Children With Diabetes and At Least One Non-Autoimmune Feature Should Be Considered for Monogenic Diabetes Testing
Context: Monogenic diabetes testing in children currently targets maturity onset diabetes in the young (MODY) or recognized genetic syndromes. Objective: We aim to determine whether genetic testing for monogenic diabetes should be performed for all children with diabetes and at least one non-autoimmune extra-pancreatic feature (syndromic diabetes). Methods: We recruited 183 children with diabetes and at least one non-autoimmune extra-pancreatic feature (50% [n = 91] with self-reported consanguinity). We measured islet-autoantibodies and type 1 diabetes (T1D) genetic risk score (T1DGRS) and used targeted next-generation sequencing to analyze all known causes of monogenic diabetes. Results: Of the children, 33% (61/183) had confirmed monogenic diabetes. Of these, 84% (51/61) had recessive etiologies with variants in WFS1 (46%), SLC19A2 (12%) and SLC29A3 (12%) being most common. Monogenic cases compared to non-monogenic had similar age of diagnosis (7.4 vs 6, P = .1) and body mass index z-score (−0.08 vs −0.41, P = .3) but had higher parental consanguinity (62% vs 19%, P = .01) and features in multiple organ systems (53% vs 28%, P = .01). Only 59% reported well-recognized features of their associated genetic syndrome. Children with low T1DGRS (<50th centile of T1D population) and negative/untested antibodies were more likely to have monogenic cause compared to positive antibodies or negative/untested antibodies and a high T1DGRS (≥ 50th centile) (48% vs 3% vs 7%, P < .0001). Conclusion: Children with diabetes and at least one non-autoimmune extra-pancreatic feature should be considered for monogenic diabetes testing. Measurement of islet-autoantibodies and T1DGRS help prioritize genetic testing.
- 1 August 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , e362-e367
Open AccessChildren With Diabetes and At Least One Non-Autoimmune Feature Should Be Considered for Monogenic Diabetes Testing
Context: Monogenic diabetes testing in children currently targets maturity onset diabetes in the young (MODY) or recognized genetic syndromes. Objective: We aim to determine whether genetic testing for monogenic diabetes should be performed for all children with diabetes and at least one non-autoimmune extra-pancreatic feature (syndromic diabetes). Methods: We recruited 183 children with diabetes and at least one non-autoimmune extra-pancreatic feature (50% [n = 91] with self-reported consanguinity). We measured islet-autoantibodies and type 1 diabetes (T1D) genetic risk score (T1DGRS) and used targeted next-generation sequencing to analyze all known causes of monogenic diabetes. Results: Of the children, 33% (61/183) had confirmed monogenic diabetes. Of these, 84% (51/61) had recessive etiologies with variants in WFS1 (46%), SLC19A2 (12%) and SLC29A3 (12%) being most common. Monogenic cases compared to non-monogenic had similar age of diagnosis (7.4 vs 6, P = .1) and body mass index z-score (−0.08 vs −0.41, P = .3) but had higher parental consanguinity (62% vs 19%, P = .01) and features in multiple organ systems (53% vs 28%, P = .01). Only 59% reported well-recognized features of their associated genetic syndrome. Children with low T1DGRS (<50th centile of T1D population) and negative/untested antibodies were more likely to have monogenic cause compared to positive antibodies or negative/untested antibodies and a high T1DGRS (≥ 50th centile) (48% vs 3% vs 7%, P < .0001). Conclusion: Children with diabetes and at least one non-autoimmune extra-pancreatic feature should be considered for monogenic diabetes testing. Measurement of islet-autoantibodies and T1DGRS help prioritize genetic testing.
- 17 February 2025
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 38 (4) , 318-325
Is oxytocin related to psychiatric symptoms in adolescents with obesity?
Objectives: We aimed to investigate the relation of oxytocin receptor (OXTR) gene variants (rs53576 and rs2254298) and serum oxytocin (OXT) levels with psychiatric symptoms in healthy adolescents and adolescents with obesity. Methods: A total of 250 adolescents with obesity and 250 healthy adolescents were included in this study. Attachment properties, anxiety, and depression were evaluated with self-reports while diagnoses were ascertained with KIDDIE-SADS-PL Turkish version. Serum OXT level was studied with the ELISA method, and OXTR gene variants were studied by quantitative polymerase chain reaction (rs53576) and restriction fragment length polymorphism (RFLP) (rs2254298) methods. Results: Serum OXT level was significantly lower in adolescents with obesity than in healthy controls. Self-reported symptoms of anxiety and depression were significantly elevated, especially in female adolescents with obesity, whereas parent/peer attachment was significantly lower. The rs53576 G/G genotype was found to be significantly more prevalent among obese youth. About 29.2 % of obese youth were diagnosed with psychopathology, especially anxiety and depression. OXT levels and receptor polymorphisms were not related to self-reported symptoms, attachment, and presence of psychopathology. Conclusions: Further studies should evaluate the roles of other constructs (e.g., early adversity, parenting, social supports, coping, temperament, etc.) and discern the roles of parent–child synchrony in elucidating relationships between OXT, pediatric obesity, and psychopathology.
- 17 February 2025
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 38 (4) , 318-325
Is oxytocin related to psychiatric symptoms in adolescents with obesity?
Objectives: We aimed to investigate the relation of oxytocin receptor (OXTR) gene variants (rs53576 and rs2254298) and serum oxytocin (OXT) levels with psychiatric symptoms in healthy adolescents and adolescents with obesity. Methods: A total of 250 adolescents with obesity and 250 healthy adolescents were included in this study. Attachment properties, anxiety, and depression were evaluated with self-reports while diagnoses were ascertained with KIDDIE-SADS-PL Turkish version. Serum OXT level was studied with the ELISA method, and OXTR gene variants were studied by quantitative polymerase chain reaction (rs53576) and restriction fragment length polymorphism (RFLP) (rs2254298) methods. Results: Serum OXT level was significantly lower in adolescents with obesity than in healthy controls. Self-reported symptoms of anxiety and depression were significantly elevated, especially in female adolescents with obesity, whereas parent/peer attachment was significantly lower. The rs53576 G/G genotype was found to be significantly more prevalent among obese youth. About 29.2 % of obese youth were diagnosed with psychopathology, especially anxiety and depression. OXT levels and receptor polymorphisms were not related to self-reported symptoms, attachment, and presence of psychopathology. Conclusions: Further studies should evaluate the roles of other constructs (e.g., early adversity, parenting, social supports, coping, temperament, etc.) and discern the roles of parent–child synchrony in elucidating relationships between OXT, pediatric obesity, and psychopathology.
- Open Access
- 2 January 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (1) , 31-37
Evaluation of Serum Advanced Glycation End Product Levels and Microvascular Complications in Children and Adolescents with Type 1 Diabetes Mellitus
Objective: Advanced glycation end products (AGEs) are irreversible macromolecules formed by nonenzymatic reactions due to chronic hyperglycemia. The aim of this study was to assess the relationship between AGEs and the microvascular complications of children and adolescents with type 1 diabetes mellitus (T1DM). Materials and Methods: Twenty-six T1DM patients with microvascular complications and 58 complication-naive patients who were similar regarding age, sex, and pubertal status enrolled in the study. Anthropometric, biochemical, ophthalmologic, and neurologic variables were compared with serum AGEs levels by the fluorescence method. Results: There was no significant difference observed between the patients with complications and those without complications in terms of serum levels of AGEs and other biochemical parameters. However, the duration of T1DM and urine microalbumin–creatinine ratio (uACR) were significantly higher in the complication-positive group (P < .001). Serum levels of AGEs were found to be similar when retinopathy, peripheral, and optic neuropathy were separately compared with the complication-naive group (P > .05). However, patients with nephropathy had significantly higher serum levels of AGEs than patients without complications (P = .023). In addition, there was a significant positive correlation between serum AGEs levels and uACR (P = .042) but not other parameters (P > .05). Conclusion: This study is the first to evaluate the association between serum AGEs levels and microvascular complications in children and adolescents with T1DM. Our study highlights that serum AGEs levels are significantly correlated with nephropathy but not with retinopathy and neuropathy. Further long-term studies with a larger sample size are required to establish a better relationship between diabetic complications and AGEs. Cite this article as: Kırkgöz T, Acar S, Küme T, et al. Evaluation of serum advanced glycation end product levels and microvascular complications in children and adolescents with type 1 diabetes mellitus. Turk Arch Pediatr. 2024;59(1):31-37.
- 2 January 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (1) , 31-37
Open AccessEvaluation of Serum Advanced Glycation End Product Levels and Microvascular Complications in Children and Adolescents with Type 1 Diabetes Mellitus
Objective: Advanced glycation end products (AGEs) are irreversible macromolecules formed by nonenzymatic reactions due to chronic hyperglycemia. The aim of this study was to assess the relationship between AGEs and the microvascular complications of children and adolescents with type 1 diabetes mellitus (T1DM). Materials and Methods: Twenty-six T1DM patients with microvascular complications and 58 complication-naive patients who were similar regarding age, sex, and pubertal status enrolled in the study. Anthropometric, biochemical, ophthalmologic, and neurologic variables were compared with serum AGEs levels by the fluorescence method. Results: There was no significant difference observed between the patients with complications and those without complications in terms of serum levels of AGEs and other biochemical parameters. However, the duration of T1DM and urine microalbumin–creatinine ratio (uACR) were significantly higher in the complication-positive group (P < .001). Serum levels of AGEs were found to be similar when retinopathy, peripheral, and optic neuropathy were separately compared with the complication-naive group (P > .05). However, patients with nephropathy had significantly higher serum levels of AGEs than patients without complications (P = .023). In addition, there was a significant positive correlation between serum AGEs levels and uACR (P = .042) but not other parameters (P > .05). Conclusion: This study is the first to evaluate the association between serum AGEs levels and microvascular complications in children and adolescents with T1DM. Our study highlights that serum AGEs levels are significantly correlated with nephropathy but not with retinopathy and neuropathy. Further long-term studies with a larger sample size are required to establish a better relationship between diabetic complications and AGEs. Cite this article as: Kırkgöz T, Acar S, Küme T, et al. Evaluation of serum advanced glycation end product levels and microvascular complications in children and adolescents with type 1 diabetes mellitus. Turk Arch Pediatr. 2024;59(1):31-37.
- Open Access
- 13 November 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220254
Genetic diagnosis of congenital hypopituitarism in Turkish patients by a target gene panel: novel pathogenic variants in GHRHR, GLI2, LHX4 and POU1F1 genes
Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation [...] ABSTRACT Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation
- 13 November 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220254
Open AccessGenetic diagnosis of congenital hypopituitarism in Turkish patients by a target gene panel: novel pathogenic variants in GHRHR, GLI2, LHX4 and POU1F1 genes
Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation [...] ABSTRACT Objective: Congenital hypopituitarism (CH) is a rare disease characterized by one or more hormone deficiencies of the pituitary gland. To date, many genes have been associated with CH. In this study, we identified the allelic variant spectrum of 11 causative genes in Turkish patients with CH. Materials and methods: This study included 47 patients [21 girls (44.6%) and 26 boys (55.4%)] from 45 families. To identify the genetic etiology, we screened 11 candidate genes associated with CH using next-generation
- Open Access
- 15 March 2023
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 4 (1) , 19-23
Results confirming the efficacy of oral L-dopa on cortisol secretion in patients being evaluated for suspected growth hormone deficiency
Objective: Adrenal insufficiency is a life-threatening disease and therefore, accurate diagnosis and prompt treatment are life-saving. The main purpose of this study was to retrospectively evaluate the serum cortisol levels measured during the L-dopa test in cases suspected GH deficiency and to compare the effect of L-dopa on cortisol secretion with the results of previous studies. Method: Between January 2019 and January 2021, patients who underwent the L-dopa test for the evaluation of GH deficiency in our Pediatric Endocrinology Clinic and whose basal cortisol levels were measured at the baseline and at the 120th minutes of the test were included. The clinical, anthropometric, and laboratory data of the patients were obtained from the medical records. Results: Eighty-five patients (38 girls, 47 boys) were included in the study. The mean age of the patients was 10.3 ± 3.5 years (range, 4.1 - 14.9 years). The mean serum cortisol level was 11.1 ± 3.6 µg/dL at baseline and 20.9 ± 3.8 µg/dL at 120th minutes (the mean cortisol increase was 9.8 ± 4.1 µg/dL). Cortisol response was adequate (> 18 µg / dL) in 76 cases (89.4%). Nausea/vomiting was observed in 53 (62.4%) of the patients during the L-dopa test. Peak cortisol responses of the cases with and without side effects were similar (20.9 ± 3.8; 20.8 ± 3.7; p = 0.945). Conclusion: In conclusion, the L-dopa test is easy to apply, effective, and safe and can be performed to evaluate cortisol adequacy at least in patients being evaluated for suspected GH deficiency.
- 15 March 2023
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 4 (1) , 19-23
Open AccessResults confirming the efficacy of oral L-dopa on cortisol secretion in patients being evaluated for suspected growth hormone deficiency
Objective: Adrenal insufficiency is a life-threatening disease and therefore, accurate diagnosis and prompt treatment are life-saving. The main purpose of this study was to retrospectively evaluate the serum cortisol levels measured during the L-dopa test in cases suspected GH deficiency and to compare the effect of L-dopa on cortisol secretion with the results of previous studies. Method: Between January 2019 and January 2021, patients who underwent the L-dopa test for the evaluation of GH deficiency in our Pediatric Endocrinology Clinic and whose basal cortisol levels were measured at the baseline and at the 120th minutes of the test were included. The clinical, anthropometric, and laboratory data of the patients were obtained from the medical records. Results: Eighty-five patients (38 girls, 47 boys) were included in the study. The mean age of the patients was 10.3 ± 3.5 years (range, 4.1 - 14.9 years). The mean serum cortisol level was 11.1 ± 3.6 µg/dL at baseline and 20.9 ± 3.8 µg/dL at 120th minutes (the mean cortisol increase was 9.8 ± 4.1 µg/dL). Cortisol response was adequate (> 18 µg / dL) in 76 cases (89.4%). Nausea/vomiting was observed in 53 (62.4%) of the patients during the L-dopa test. Peak cortisol responses of the cases with and without side effects were similar (20.9 ± 3.8; 20.8 ± 3.7; p = 0.945). Conclusion: In conclusion, the L-dopa test is easy to apply, effective, and safe and can be performed to evaluate cortisol adequacy at least in patients being evaluated for suspected GH deficiency.
- 15 December 2022
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 3 (4) , 170-173
The Importance of Thyroid Function Tests in a Patient Presenting with Precocious Menarche: Van Wyk Grumbach Syndrome
- 15 December 2022
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 3 (4) , 170-173
The Importance of Thyroid Function Tests in a Patient Presenting with Precocious Menarche: Van Wyk Grumbach Syndrome